{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:40Z","timestamp":1793805940428,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.05.026","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:04:23Z","timestamp":1781827463000},"page":"195-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Gu\u00e9rin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled cohort clinical study"],"prefix":"10.1016","volume":"44","author":[{"given":"Aya A","family":"Zahran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-3215","authenticated-orcid":false,"given":"Ahmed A","family":"Shokeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Saad","family":"Serria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Awadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"El-Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Elshabrawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina A","family":"Baiomy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.05.026_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0002","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/iju.15263","article-title":"Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: evidence update of surgical concept, risk stratification, and BCG-treated disease","volume":"30","author":"Miyake","year":"2023","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0003","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1136\/jitc-2022-005518","article-title":"Original research: intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections","volume":"11","author":"Van Puffelen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0005","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0006","doi-asserted-by":"crossref","first-page":"295","DOI":"10.31083\/j.fbl2908295","article-title":"Update on the mechanism of action of intravesical BCG therapy to treat non-muscle-invasive bladder cancer","volume":"29","author":"Chakra","year":"2024","journal-title":"Front Biosci - Landmark"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.026_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-95157-6","article-title":"MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model","volume":"11","author":"de Queiroz","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fruro.2023.984967","article-title":"Mutations in genes encoding innate immune molecules identified in bladder cancer samples as potential biomarkers for immunotherapy with BCG and agonists","volume":"3","author":"de Queiroz","year":"2023","journal-title":"Front Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.026_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s44272-024-00023-x","article-title":"MyD88\u2019s function in the emergence and growth of tumors","volume":"3","author":"Liu","year":"2024","journal-title":"Clin Cancer Bull"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.ircmb.2017.07.007","article-title":"NF-\u03bab and the transcriptional control of inflammation","volume":"335","author":"Mitchell","year":"2018","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0012","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1055-9965.EPI-18-0893","article-title":"Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle-invasive bladder cancer","volume":"28","author":"Salmasi","year":"2019","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ijms25010144","article-title":"Longitudinal transcription profiling of bladder cancers dictate the response to BCG treatment and disease progression","volume":"25","author":"Lee","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0014","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 Classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0017","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ajhp\/zxaf044","article-title":"KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: a primer on what pharmacists need to know","volume":"82","author":"Awdishu","year":"2025","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0018","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-10-193","article-title":"Expression and significance of the TLR4\/MyD88 signaling pathway in ovarian epithelial cancers","volume":"10","author":"Kim","year":"2012","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajur.2021.05.002","article-title":"Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer\u2014analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I)","volume":"9","author":"Thyavihally","year":"2022","journal-title":"Asian J Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0021","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to intravesical BCG in non\u2013muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0022","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11255-019-02183-5","article-title":"Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics","volume":"51","author":"\u015alusarczyk","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-08486-0","article-title":"A novel immune-related gene pair prognostic signature for predicting overall survival in bladder cancer","volume":"21","author":"Fu","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100122","article-title":"The critical role of toll-like receptor-mediated signaling in cancer immunotherapy","volume":"14","author":"Chen","year":"2022","journal-title":"Med Drug Discov"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/01.ju.0000168619.25341.96","article-title":"Interferon-\u03b3 up-regulates toll-like receptor 4 and cooperates with lipopolysaccharide to produce macrophage-derived chemokine and interferon-\u03b3 inducible protein-10 in human bladder cancer cell line RT4","volume":"174","author":"Yamada","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0026","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1128\/IAI.72.4.2400-2404.2004","article-title":"MyD88-Deficient mice display A profound loss in resistance to mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression","volume":"72","author":"Scanga","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tice.2018.03.011","article-title":"Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-gu\u00e9rin (BCG) in non-muscle invasive bladder cancer","volume":"52","author":"Dias","year":"2018","journal-title":"Tissue and Cell"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0028","first-page":"65","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.651560","article-title":"Toll-like receptor 4 as a favorable prognostic marker in bladder cancer: a multi-omics analysis","volume":"9","author":"Lu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0030","first-page":"1","article-title":"Identification and construction of prognostic clusters and risk-prognosis model based on aging-immune related genes in bladder cancer","volume":"15","author":"Cao","year":"2024","journal-title":"Discov Oncol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0031","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1016\/j.clnu.2021.10.019","article-title":"Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer","volume":"40","author":"Ke","year":"2021","journal-title":"Clin Nutr"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0032","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s11255-020-02438-6","article-title":"Smoke load prognostic impact on bacillus Calmette\u2013Gu\u00e9rin (BCG) treated non-muscle invasive bladder cancer","volume":"52","author":"Andrade","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0033","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.urolonc.2020.02.016","article-title":"Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Gu\u00e9rin after transurethral resection of the bladder tumor","volume":"38","author":"Ferro","year":"2020","journal-title":"Urol Oncol: Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.655000","article-title":"Lymphocyte-to-monocyte ratio is the independent prognostic marker of progression in patients undergoing BCG-immunotherapy for bladder cancer","volume":"11","author":"Adamkiewicz","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/cancers18020249","article-title":"Impact of computational histology AI biomarkers on clinical management decisions in non-muscle invasive bladder cancer: a multi-center real-world study","volume":"18","author":"Packiam","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.026_bib0036","doi-asserted-by":"crossref","first-page":"301","DOI":"10.48083\/EABM2528","article-title":"Urinary tumor DNA-based diagnosis and surveillance for nonmuscle-invasive bladder cancer\u2014current landscape and Future directions","volume":"4","author":"Org","year":"2023","journal-title":"Soci\u00e9t\u00e9 Int d\u2019Urologie J"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600551X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600551X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:29:14Z","timestamp":1793802554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600551X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S107814392600551X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of toll-like receptors, myeloid differentiation factor 88, and nuclear factor kappa-B regarding the response to Bacillus Calmette-Gu\u00e9rin intravesical therapy in patients with high-risk non-muscle-invasive bladder cancer: A controlled cohort clinical study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}